// App-Quantinova.ai

EP1337 : RAVULIZUMAB AND ECULIZUMAB REDUCE TRANSFUSIONS IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: EVIDENCE FROM THREE REAL-WORLD DATABASES: TRINETX US EMR, TRINETX US CLAIMS AND KOMODO HEALTH

Researchers

Presenter

  • Ioannis Tomazos

Principal Investigators

  • Anita Hill

  • Minying Royston

Medical Centers

  • Alexion Pharmaceuticals, Inc., Boston, United States

  • Miami Cancer Institute, Miami, FL, United States

  • Alexion Pharmaceuticals, Inc.,Leeds,United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved